List of Vendor Companies in France - 105

3-D Matrix is a medical device company that offers innovative peptide technology, revolutionising the way healthcare professionals manage oozing bleeding during surgery. Headquartered in Tokyo, Japan, 3-D Matrix has expanded across America, Europe, Middle East and Asia. The company collaborates with many researchers, surgeons, healthcare providers and distributors across the world to continually improve on our product. We keep patient outcome at our heart, operating on three main principles: agility, proactiveness and focus. Follow us on Twitter @3dm_emea Sign up to our newsletter for the latest clinical data and product announcements: https://news.3dmatrix.com/newsletter-subscription

Specialized in cell culture, Abcell-bio has a 10-year background and experience in Stem Cell Research and Development. Abcell-bio team is composed of experts that can advise you for your research projects. Our technical team is trained to produce high-quality products in the fields of hematopoiesis and vascular biology. We can process several cell types extracted from: * Cord Blood: CD34+ cells, CD133+ cells, CD34- cells, MonoNuclear Cells (MNCs), Endothelial Progenitor Cells (EPCs) * Umbilical Cord (Human Umbilical Vein/Arterial Endothelial Cells (HUVEC, HUAEC) We also created Cell Culture Media to match your needs for these particular cell types. Please contact us for more information

Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms. Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanist ambition. Determined to become a key player in the transformation of manufacturing, we combine our expertise in biology, fermentation, IT, robotics, analytics and industrial property to reinvent the future of numerous industries - from food to healthcare, cosmetics and chemicals. We help industries make the ecological transition by rethinking their production models We rely on biotechnologies and the untapped potential of micro-organisms to develop new bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. We take up the industry's current challenges by: ·      Using renewable raw materials ·      Relocate essential production and secure supply chains ·      Designing biocompatible products less toxic for the environment ·      Reducing greenhouse gas emissions Abolis is providing tailor-made industrial solutions, based on microorganisms Because each customer has its own unique story and challenges, we cultivate a multidisciplinary, tailor-made approach. Science, economics, intellectual property, industrial realities: each of our answers is based on the best possible practices. Thanks to our advanced knowledge of micro-organisms, we combine chemistry and biology, paving the way for a more sustainable future. We are… independent in thought and action rigorous in our approach and the way we work creative because we never stop innovating, while remaining pragmatic ambitious because we are passionate and determined to make a difference

🚀 Aenitis designs, develops, and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. By precisely controlling levitated cells with sound waves, our systems handle cells in full sterile conditions and radically increase productivity while preserving the native state of cells at every step of the engineering process. This technology enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing for the handling of tens of milliliters per minute. Such capabilities are critical for scaling applications from research to clinical and industrial use. 💡Today, we have achieved proof-of-concepts for our contact-free & label-free proprietary technology across multiple cell types & processes. Mitis™, our flagship product, is already used for a wide range of applications, including cell sorting, isolation, concentration & washing, from research to clinical and industrial scale. 🌍Co-founded by pioneers of acoustic levitation & fluid mechanics and a biotech entrepreneur, the company benefits from the support of the European Commission & the French Government and from the commitment of leading investors, notably the European Investment Bank and Seventure Partners.

AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. We are growing and hiring! Check our career website: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA on our Welcome To The Jungle page: https://www.welcometothejungle.com/fr/companies/aqemia

Argolight is specialized in integrated fluorescence quality management Pharmaceutical, diagnostics and biotech companies use our tools to make their fluorescence-based measurements more reliable. They reduce maintenance downtime, cost and gain a greater visibility over the state of their systems fleets. Our tools are specially tailored for intensively used systems and environment where quality is important. We invented a patented technology that enables our clients to compare results performed on different systems and monitor data on a large scale. The solution allows system wide diagnosis in 5-15 minutes instead of a day, thus reducing the downtime of the machine, increasing productivity while insuring quality management. As OEM, we provide manufacturers with solution to monitor their fleets enabling cross-systems data mining. Contact us, to see how you can get more from your fluorescence measurements. 

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies.

At Aton, we're building a team of expert companies dedicated to accelerating the progress of tomorrow's therapies. To help deliver the right treatment, to the right patient, at the right time. Aton's Ecosystem – Lifescience platforms united to transform therapies Our platforms are driving a fundamental shift in how medicines are developed. Toward products and services adapted to the patient's biology. Complimentary cutting-edge businesses, with unique technologies and diverse teams of experts. One goal. To accelerate discoveries for the good of patients, medicine, and society. Aton's platforms guide and support life-science businesses to achieve their goals with greater efficiency. Our Strategy We're driven by our ambition to develop tomorrow's therapies. We invest in, guide, support, and develop lifesciences companies with unique technologies. Our strategic investments focus on advancing personalized medicine. We collaborate with the brightest entrepreneurs, to provide flexible and longterm support. To ensure they reach their full potential — to help advance today's and tomorrow's medicines. To transform patient outcomes for good. Many specialists, working as one team, we're constantly moving forward, to take our place at the cutting-edge of medical advancements. We see the future of health. It's safer, targeted and more effective. We understand what it takes to deliver to health and regulatory requirements. Helping make this future a reality.

Bcv is a french Medtech company spin-off from the Intelligent Robotic Systems Laboratory (ISIR) at Sorbonne University and the Rothschild Foundation Hospital in Paris. A multidisciplinary team developing innovative technologies for endovascular procedures, for immediate improvement and future applications. Our first focus? STROKE Discover our actuable guidewire with electronically controllable shape-ability designed for the interventional neuroradiology procedures. Objective? Enhance endovascular access & navigation in any anatomy. Our first-ever Shape Memory Alloy actuated system is : - Suitable for minimally invasive interventions, - Unique, a single solution that could replace the package of traditional devices, - Ergonomic, its unique smart handle allows electronic actuation and a controllable torque of the catheter tip robotically to conform to arterial tortuosities, - Compatible and complementary with Robotics and Image Guided Therapy, in a patient-oriented specific design. Objective ? Reach the most complex parts of the human body, providing a game-changer solution for endovascular minimally-invasive procedures. Caution: Investigational device, not yet available for commercial sale, worldwide.

To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.

BIOBank is a leader providing high-quality bone allografts to surgeons in orthopaedics, maxillofacial, and dental surgery. Our bone grafts are sourced from living donors in France & processed via our perfected Supercrit® technology, providing key advantages to surgeons and patients: - Total viral-inactivation - Maintainance of biomechanical and structural intergrity of the tissue - Availability in various shapes & forms, allowing easy handling during the surgical procedure - High quality bone integration, improving patient recovery BIOBank assure l’ensemble des activités d’une banque de tissus, de la prise en charge des tissus (recueil) à la délivrance de greffons sécurisés. Ces étapes comprennent, entre autres, la sélection biologique des donneurs puis la transformation proprement dite des greffons osseux.

BIOCORP is a French company specializing in connected devices. Since October 2023, BIOCORP is a 100% Novo Nordisk company. The production plant is located in Issoire and the R&D and operational support teams in Cournon d’Auvergne. Every day, our 100 employees are mobilised around a single objective: to offer professional innovative solutions improving the daily life for patients. We develop innovative connected devices helping in the management of various diseases. As an example, we are offering Mallya, a medical device dedicated to patients living with diabetes, turning any insulin pen into a smart device. Our company is growing quickly but will not lose its start-up spirit! Do you have the taste for challenge and want to join a team focused on innovation, ready to reinvent itself every day? At Biocorp, we work with agility, for quality results and persistently in the aim of innovating. All of this in an environment that constantly seeks to promote well-being at work. Are you looking for a professional environment in which you can evolve, where your job is not a fixed definition of who you are, but the starting point of a career? Come and join us!

bioMérieux develops in vitro products to diagnose infectious diseases, cancer and cardiovascular disease and to detect microorganisms in agri-foods, pharmaceuticals and cosmetics.BioFire COVID-19 test

Biopredic International is committed to support Life Science Research by developing and distributing biological tools. We assist both academia and industries in drug development, drug discovery, cosmetic and chemical fields. Biopredic International delivers assays, tissues, cells and reagents including: > High quality hepatocytes (human and animal, fresh or cryopreserved) and other liver-derived products (microsomes, S9 fractions and cytosols) > Skin products (fresh or frozen), including human skin discs and skin sheets (full thickness, dermatomed, stratum corneum), skin cells (keratinocytes, fibroblasts), subcellular fractions… > Blood products, including whole blood, sera, plasma, PBMCs, lymphocytes, monocytes, dendritic cells, CD34… > And other products such as biofluids (bile, gastric & intestinal fluids), non-standard human and animal tissues Applications include: - toxicology - genotoxicity - metabolism - passage - bioanalysis - and tranporter analysis. Biopredic International is also the exclusive worldwide licensor of HepaRG®, the human hepatic stem cell line patented by the French National Instituteof Health and Medical Research. Google+: https://plus.google.com/+BiopredicInternationalSaintGrégoire/posts Twitter: https://twitter.com/Biopredic_Intl To apply for a position at Biopredic International please send your CV and cover letter to recrutement[at]biopredic.com

Bioréa relies on 10 years of expertise and our innovative & patented technology of closed air-lift bioreactor. Our core businesses are: - Cultivation of different micro-organisms (microalgae, yeast, bacteria) for nutrition & health, cosmetics, pet-food, animal feed and aquaculture. - Tailor-made biomass projects, liquid or powder, ready to use or for extraction. From R&D to production.

BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global Unmet Medical Needs : Available, Affordable, Sustainable. BioSourcing changes the design paradigm of these new biotherapeutics thanks to the mastery of several breakthrough technologies including genome editing (CRISPR). The BioSourcing disruptive approach leads to a drastic reduction in capital requirements and production costs, especially for large volumes, as well as an improvement in the quality/efficiency of biopharmaceuticals through better glycosylation. BioSourcing strongly contributes to sustainable development, in particular in drasticly reducing the carbon footprint. BioSourcing is a fully operational biotechnology company, based in Liège, Belgium. Its team is made up of the best scientists, international experts in their field and has developed strategic partnerships with leaders in the pharmaceutical and biotechnology industry.

Créée en 2005 et basée à Strasbourg en Alsace, la société BIOSYNEX conçoit, fabrique et distribue des Tests de Diagnostic Rapide (TDR). Dans leur version professionnelle, ils offrent une meilleure prise en charge médicale des patients grâce à la rapidité de leur résultat et à leur simplicité d'utilisation. Dans leur version autotest, ils permettent au grand public une autosurveillance de diverses pathologies assurant ainsi une meilleure prévention et accélérant la demande de soins. Leader sur le marché des TDR en France, BIOSYNEX est le seul acteur à maîtriser intégralement sa chaîne de valeur grâce à sa plateforme technologique déclinable sur de nombreuses applications et adaptée à différents types d'utilisateurs tels les laboratoires, les hôpitaux, les médecins et le grand public. Acteur majeur de la santé publique avec 140 collaborateurs et une gamme de 1700 références en France dont notamment le test Exactop du dépistage du HIV, BIOSYNEX a reçu en novembre 2017 les prix de l'Innovation dans la catégorie Biotech & Science de la vie et le prix de la société cotée Euronext au palmarès national du Deloitte In Extenso Technology Fast 50. Plus d'informations sur www.BIOSYNEX.com BIOSYNEX was founded in 2005 and is one of the most significant European manufacturers and provider of rapid membrane tests in the in-vitro diagnostic market. By staying close to our customers and business partners we are aware of the needs and expectations they may have of our products and services. Listening to their voice, together with the help of our Research and Development laboratories in France and our state of the art manufacturing facilities, allows us to identify new applications in rapid testing, develop and launch innovative products and provide high quality services. Our aim is to provide innovative diagnostic tests to help physicians make fast and better medical and therefore lifesaving decisions.

Bio-Xtal is historically a provider of structural biology services. Since twelve years, our know-how in structural biology allowed us to perform projects ranging from domain definition to the structure resolution of protein/ligand or protein/protein interactions by Xray crystallography and NMR. We put an emphasis on monitoring the activity of our targets to ensure the relevance of the structural data we deliver. Our policy is to systematically develop home designed activity assays during our structural biology projects. Mastering eukaryotic and prokaryotic expression systems allows us to supply high quality protein for the needs of your compound screening as well as for structural studies of the selected compound’s complexes, guarantying the coherence of the results obtained on both sides A new key service from of Bio-Xtal is the cytosoluble single chain antibody fragment selection (Cytobody™). These can be raised against any antigen within a very short delay (4 weeks) and are very well expressed in either mammalian or bacteria cells. This allows their expression in Coli for large scale production and expression within mammalian cells for cellular biology applications. The applications of the Cytobodies ranges from the discovery of new druggable sites in multi-domain proteins to immuno-detection, cell imaging, protein purification, and protein stabilisation.

CAPACITÉS is the subsidiary of University of Nantes, dedicated to the development of research. Specialized in engineering of innovative projects, CAPACITÉS exploits the latest scientific discoveries necessary for the performance of its customers. Springboard to differentiate in the ever-changing markets, areas of activity extend to technological and engineering sciences, human and social sciences and health. The activities of CAPACITÉS have advanced expertise on specific and cross-cutting themes. From idea generation to their implementation, CAPACITÉS impulse with its customers a strong value creation process through the development of R&D of high level dedicated to nine economic sectors.

Caranx Medical is a healthcare technology company based in Nice, France, founded by a team of experts including an entrepreneur, a clinician, and a researcher. The company focuses on enhancing access to less invasive medical care through innovative technologies. Its mission is to standardize complex surgical procedures, reduce risks associated with human error, and improve outcomes for patients and healthcare providers. The company specializes in developing intelligent robotic systems to improve surgical precision. One of its key products is the TAVIPILOT, a robotic solution designed for aortic valve procedures. Caranx Medical is also advancing the field with TAVIPILOT Soft, an AI software for real-time guidance during heart valve implantation, which is set for FDA submission in January 2025. The company has achieved significant milestones, including the world's first robotic-assisted heart valve implantation in an animal in April 2024. With a diverse team of over 20 professionals skilled in robotics, software management, and artificial intelligence, Caranx Medical is committed to driving innovation in interventional cardiology and improving patient care worldwide.

Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single-cell isolation and bioprinting : Ability to manipulate single-cell has long been a challenge for the scientific community due to their micrometric size and delicate nature. Cellenion has developed and patented CellenONE, a breakthrough single cell isolation and dispensing technology. CellenONE provides outstanding single cell precision, high throughput, and unmatched recovery. Bioprinting is the process of generating spatially-controlled cell patterns using 3D printing technologies. Cellenion will aim toward both miniaturization and automation in order to produce reproducible models of different complexities.

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Clarteis is a French company located in Sophia Antipolis, known for its innovative dermatology medical devices. The company develops and manufactures CE-certified and FDA-approved products, emphasizing quality and innovation. Clarteis holds ISO 13485:2016 certification, ensuring high standards in its production processes. One of its key products is the exciplex®, a portable monochromatic excimer light device designed to treat various localized autoimmune skin conditions, including alopecia areata, vitiligo, psoriasis, atopic dermatitis, and mycosis fungoides. Clarteis has a global presence, with its products approved in over 45 countries, including the USA, Europe, and Japan. The company also offers support and resources for its products through a network of distributors and partners, promoting collaboration in the dermatological field.

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

CliniSciences commercialises reagents (antibodies, recombinants, ELISA kits, RNAi, cDNA clones, probes, PCR/qPCR reagents...) to diagnostic and research labs. As very dynamic company, we do our best to be close to our customers'​ needs in terms of high quality reagents that we propose and in terms of service that we provide (search for a particular antibody, technical support, delivery time, etc.) Our principal assets for better serving you : adaptability, flexibility, reactivity and naturally the competence of the technical specialists at your service.

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com

New technologies for protein design.

CSBio is a leading peptide and peptide synthesizer manufacturing company located in Silicon Valley, California. For over 30 years, CSBio has been producing automated peptide synthesizers, high quality custom peptides, and cGMP peptides for the global pharmaceutical community. Our peptide products and peptide synthesis equipment can be found in peptide production laboratories and pharmaceutical companies worldwide.

Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus for Cure51 is initially to start with 3 types of particularly agressive cancers and will naturally expand to other indications and therapeutic areas to capitalize on its exclusive and unprecedented set of data and discovery pipelines.

DavosPharma is a leading provider of discovery, chemistry, biology, and formulation services. We provide scientific expertise and technical and regulatory support during drug development for academic institutions, emerging biotech, and established multinationals. In an increasingly fragmented marketplace, DavosPharma strives to deliver the best solutions for your specific needs, timelines and budgets. We are unique in the industry because we are paid on deliverables, not ‘best effort'. DavosPharma has a 40 year track record of continuous success. Benefit from our experience and talent.

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform's features and data.

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

Receiving blood is receiving life. DIAGAST's goal is to help healthcare professionals transmit life with the help of the best blood group determination technologies. Even though it is not always a matter of life and death, transfusion errors are never acceptable. Over the last 30 years, DIAGAST has developed unparalleled expertise and know-how in the transfusion sector. DIAGAST develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST also ensures the research, manufacturing and marketing of all its products. Moreover, DIAGAST offers a wide range of related services, such as a training center for their automated systems, a hotline and on-site follow-up on automaton calibration. We even make control and measurement tools available over the Internet. DIAGAST is now the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions.

D.I.V.A. Expertise est une société de conseil, de stratégie et de développement en recherche scientifique dans les domaines de la Santé, de la Nutrition, de la Cosmétique et de l'Esthétique. Ses objectifs sont de soutenir les industriels dans la structuration, l'organisation et le développement de leur recherche afin d'optimiser ses coûts, délais et résultats. L'accompagnement personnalisé par nos experts dynamise le processus R&D d'un produit en promouvant Créativité, Innovation et Collaboration. Son cœur d'expertise est ciblé sur la biologie du tissu graisseux dit adipeux, reconnu comme organe endocrine avec un rôle fondamental et central sur l'homéostasie générale. Le partage de compétences, de valeurs scientifiques et humaines est à l'origine de la constitution de l'équipe de D.I.V.A. Expertise. A l'interface de quatre mondes Académique, Industriel, Médical et Chirurgical, D.I.V.A. Expertise a créé un réseau regroupant des experts multidisciplinaires et de renommée internationale dont elle assure l'animation et la coordination. D.I.V.A. Expertise (Développement, Innovation, Valorisation, Action en recherche) Ensemble, Embellissons la Recherche Pour plus d'informations, visitez notre site : www.diva-expertise.com Pour nous contacter, écrivez-nous : contact@diva-expertise.com

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

Pionner and leader in crop innovation software, since 1984, managing up to 250K agronomic trials per year. Doriane empowers your agronomy department in its digital transformation. Optimize your data, automate your workflows, and make agile decisions! We support innovation in agronomy—whether in the field, lab, or office—to tackle environmental, economic, and human challenges. We offer digital solutions to collect and enhance data for better decision-making. Our goal is to help agronomy teams adopt practices that are more effective, efficient, open, and resilient. Leverage our extensive experience in project management, technology complexity, cyber-security compliance, and evolving scientific knowledge. We bring our full ambition to every project, working closely with customer teams. Our Customer Success Service is fully engaged throughout the project lifecycle to ensure maximum user adoption. Choosing Doriane means more than just acquiring new software; it's embarking on a digital transformation journey with a partner who supports you at every stage to maximize your benefits. Bloomeo agro-testing software manages the evaluation of varieties, inputs, biosolutions, or practices with a systemic approach, emphasizing the environmental context of field data. Bloomeo BioSolutions evaluates the conditions under which a biosolution performs optimally. Bloomeo Product Development software supports product development activities in agronomy: aligning product design with market segments, managing multi-environment trials, standardizing data collection, and optimizing team collaboration. RnDExperience software supports all stages of the breeding process, from crossing to selection and evaluation. Our motto is “Agronomy driven by data!” and stakeholders worldwide appreciate making informed decisions based on meaningful information. Let's discuss your project: https://www.doriane.com/book-a-demo

ELICIT PLANT is an AGtech company and a pioneer in the stimulation of field-grown plants through the use of phytosterols. By reducing plant water stress, our patented technology increases yield in situation of lack of water. Elicit Plant develops and provides new effective prevention products against the stress suffered by plants grown by the intake of exogenous phytosterols in the field. Elicit Plant offers a novel solution for reducing water consumption for the cultivation of targeted plants and helps to fight against water stress. Elicit Plants develops a methodology to collect soil, plant development and climate data to quantify the results obtained under real-life conditions.

🔬 About ENTEROSYS At ENTEROSYS, we are science enthusiasts 🧪 driven by a conviction deeply rooted in medical history: for over two millennia, it has been acknowledged that the key to understanding many diseases lies in our digestive system and its interactions with other organs. Based on this ancient wisdom, we have embraced a modern and holistic approach focused on digestive physiology and the communication between the gut and peripheral organs. Specializing in the preclinical evaluation of compounds with therapeutic potential 💊, we utilize cutting-edge techniques to analyze physiological parameters in real time. Our unique expertise enables the development of proof of concept and precise study of the mechanisms of action of molecules aimed at preventing risk factors or treating diseases, including neurodegenerative 🧠 and metabolic disorders. Key Figures: Over 7️⃣ years of experience in preclinical CRO (Contract Research Organization) services 🔬. Over 7️⃣5️⃣% of clients are satisfied with our services and commission one or more additional studies 🤝. Over 5️⃣0️⃣0️⃣ scientific publications produced by the company's co-founders 📚. Our Services: Customized R&D projects 🗝️ to test therapeutic compounds. Innovative studies to differentiate in competitive markets 🚀. Revolutionary methods to speed up asset development 🛠️. A broad range of Unique Technologies: Accelerate the development of your assets with our revolutionary methods 🛠️. Diverse Testing: We provide a wide range of tests for the dermocosmetic 💄, nutraceutical 🌱, and pharmaceutical industries 🏥. Our Mission: To provide innovative preclinical solutions and advanced preclinical models to enhance and strategically position your molecules 💡. At ENTEROSYS, each client receives personalized support tailored to their specific needs 🎯.

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe (Saint-Aubin-lès-Elbeuf and Vertolaye in France, Brindisi in Italy, Frankfurt in Germany, Budapest in Hungary and Haverhill in the UK), EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris. OUR VISION Reinventing active ingredient solutions to sustainably meet clients’ and patients’ needs around the world in a sustainable way. OUR MISSION We work passionately every day to develop, manufacture and supply active-ingredient solutions for our healthcare partners around the world. We combine our scientific excellence with industrial expertise and a wide range of technologies to deliver solutions that meet the highest quality, social and environmental requirements - all while ensuring stakeholder satisfaction. OUR FUNDAMENTALS We are driven by the success of our clients and their satisfaction * Reliability * EUROAPI is the leading small molecules API player with an unique European industrial platform and proven track record for reliability. * Quality * EUROAPI provides you with active ingredients that meet the highest pharmaceutical standards. * Premium Client Service * EUROAPI manufactures your success through tailored solutions and a long-term partnership approach that provides peace of mind.

Le groupe Eurobio Scientific est un acteur intégré français du diagnostic in vitro. Aujourd'hui, leader sur le marché français du diagnostic in-vitro, le groupe Eurobio Scientific poursuit son développement en intervenant de la recherche à la commercialisation de produits diagnostiques de spécialités et de produits dans le domaine des sciences de la vie. Le savoir-faire d'Eurobio Scientific repose sur la commercialisation de tests de diagnostic de spécialité auprès des laboratoires d'analyses de biologie médicale hospitaliers et privés. Le groupe est également reconnu en France comme étant le leader du marché des tests HLA pour la transplantation. Eurobio Scientific commercialise également en exclusivité des tests et des solutions automatisées conçus par nos partenaires industriels étrangers (américains, coréens, européens…) dans les domaines des maladies infectieuses, de l'auto-immunité et des contrôles qualité. Une offre de qualité : - Une gamme de réactifs et d'instruments dédiés aux laboratoires des sciences de la vie. - Fabrication de ses produits propriétaires en interne, dans l'unité de production implantée dans les locaux de son siège, dans une salle blanche de plus de 400 m² permettant la fabrication d'unité stérile. Production de qualité, appréciée des clients d'Eurobio. Un portefeuille étendu et diversifié de produits propriétaires dans quatre spécialités : la transplantation, les maladies infectieuses, les sciences du vivant et le cancer.

DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market. ●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration. Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization. ●●● Galenix Innovations includes 6 different innovative technology platforms focusing on drug delivery solutions for life cycle management, new chemical entities and Biologicals using conventional medicinal presentations or its own patented technologies. « Patients are central to our approaches » Galenix team is focusing to preserve and/or to increase market shares on products through differentiation in accordance with regulations.

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. It's going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldn't be a direct result of the surgeon's state of mind. We believe it's possible to create tools that will improve both patient outcome and surgeon experience. We believe it's unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europe's best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. We're all in. We're still hiring.

GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.

PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

GenoSafe is a CRO providing analytical testing services for the evaluation of quality, safety and efficacy of Gene and Cell therapy candidates including : - GLP biodistribution, shedding and immunogenicity studies ; - QC testing, such as viral titration, safety and potency/efficacy testing ; - GCP bioanalysis of patient samples, including immunogenicity, shedding and gene expression studies. GenoSafe brings more than 15 years of experience in the development, qualification and validation of key analytical methods for product and sample testing.

Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. Headquartered in Lyon, France, genOway serves clients in 380 academic institutions and 170 life sciences companies, including 17 of the top 20 pharma.

Global Bioenergies substitue des produits d'origine pétrolière par des produits d'origine naturelle. En quête de naturalité sans compromis sur la performance, les acteurs de la cosmétique sont les premiers clients de la Société. Dès 2027, la Société exploitera son procédé innovant dans une usine de grande envergure. A horizon 2030, la Société prévoit de devenir un des leaders de l'immense marché émergent des carburants d'aviation durables afin de lutter contre le réchauffement climatique. Global Bioenergies est cotée sur Euronext Growth à Paris (FR0011052257 – ALGBE). L'Oréal est son premier actionnaire avec 13,5% du capital. Global Bioenergies substitutes products of fossil origin with products of natural origin. In their quest for naturalness without compromising on performance, the cosmetics players are the Company's first customers. By 2027, the Company will be operating its innovative process in a large-scale plant. By 2030, the Company plans to become a leader in the huge emerging market for sustainable aviation fuels, in order to fight against global warming. Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 - ALGBE). L'Oréal is its largest shareholder, with a 13.5% stake.

GOURMEY is France's pioneering cultivated meat company. 🌎 We create sustainable cultivated meat delights for an uncompromising and conscious generation. > Join.gourmey.com

HalioDx utilizes a proprietary set of Immune biomarkers, advanced image analysis technologies and a unique know-how to develop, manufacture and commercialize immune-based diagnostics services and products.

Ikonisys is a cell based diagnostics company, that markets the proprietary Ikoniscope® Digital Microscope, designed to deliver highly accurate and reliable detection of rare cells. Utilizing advanced molecular and immunological markers, Ikoniscope-built applications are extensively used in the US and Europe for the diagnosis of a variety of cancers.

Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors. IMPLANET focuses on spine and knee products. Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation. Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals. IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.

Climate change is the challenge of our generation. As innovators, we believe disruptive technology can bring performant solutions to the most dire challenges we face as a society. As we seek a more respectful way of living on our planet, nature itself has much to offer and teach us, starting with feeding the world of tomorrow with better nutrients - for animals, people and our planet - through insects. At Innovafeed, we are committed to inventing efficient technologies that reproduce Nature's processes on a large scale. By building a circular and zero waste agri-food chain replicating insect's role in nature, we want to reinvent our way of living with higher quality, sustainability and resilience, for everyone. We are a team of pragmatic dreamers who believe performance and positive impact can go hand in hand to reshape the world we leave to future generations.

Créé en 1964, l’Institut national de la santé et de la recherche médicale (Inserm) est un établissement public à caractère scientifique et technologique, placé sous la double tutelle du Ministère de l’Enseignement supérieur et de la recherche et du ministère de la Santé. Ses chercheurs ont pour vocation l’étude de toutes les maladies, des plus fréquentes aux plus rares, à travers leurs travaux de recherches biologiques, médicales et en santé des populations. L’Inserm, chercheur en santé depuis 1964 Avec un budget 2013 de 927 M€, l’Inserm soutient près de 300 laboratoires répartis sur le territoire français. L’ensemble de ses 1200 équipes regroupe près de 15 000 chercheurs, ingénieurs, techniciens, gestionnaires, hospitalo-universitaires, post-doctorants…Il est actuellement dirigé par Yves Levy. L’Inserm est membre de l’Alliance nationale pour les sciences de la vie et de la santé, fondée en avril 2009 avec le CNRS, le CEA, l’Inra, l’Inria, l’IRD, l’Institut Pasteur, la Conférence des Présidents d’Université (CPU) et la Conférence des directeurs généraux de centres hospitaliers régionaux et universitaires. Cette alliance s’inscrit dans la politique de réforme du système de recherche visant à mieux coordonner le rôle des différents acteurs et à renforcer la position de la recherche française dans ce secteur par une programmation concertée. L’Inserm célèbre ses 50 ans en 2014.

Construit au cœur de l'Hôpital national des 15-20, l’Institut de la Vision est l’un des plus importants centres de recherche intégrée sur les maladies de la vision en Europe. Conçu comme un lieu de rassemblement et d’échanges, il réunit sur un même site la recherche fondamentale, clinique et industrielle, favorisant ainsi le partage des concepts et des techniques, la rencontre de compétences et d’expertises complémentaires et l’émergence de nouvelles pistes de recherche. Chercheurs, médecins et industriels y travaillent de concert pour découvrir et valider ensemble de nouvelles thérapeutiques, des solutions préventives, ainsi que des technologies compensatrices des atteintes visuelles.

Situé à Paris au cœur du plus grand centre hospitalier européen, l'hôpital de la Pitié-Salpêtrière, l’Institut de Myologie est né en 1996 sous l’impulsion d’une association de malades et parents de malades, l’AFM-Téléthon. Son objectif : favoriser l’existence, la reconnaissance et l’essor de la Myologie, science et médecine du Muscle, en tant que discipline à part entière. Qu’il soit sain, malade, accidenté, sportif, vieillissant… le muscle, dont dépend notre activité et nos fonctions vitales, est devenu un véritable modèle d’innovation pour la recherche scientifique et médicale et un enjeu de santé publique. L’Institut de Myologie coordonne, autour du malade, la prise en charge médicale, la recherche fondamentale, la recherche appliquée, la recherche clinique et l’enseignement. C’est un centre de référence international qui participe à de nombreux essais et études cliniques concernant principalement les maladies neuromusculaires mais également les lésions musculaires liées au sport de haut niveau ou au vieillissement. Depuis 2005, l’Institut de Myologie est une association régie par la loi du 1er juillet 1901 dont les membres fondateurs sont l’AFM-Téléthon et Généthon. L’Association Institut de Myologie a pour mission de faciliter la coordination des activités du site, en partenariat avec cinq tutelles publiques : AP-HP, CEA, Inserm, Sorbonne Université (ex-Université Pierre et Marie Curie) et CNRS.

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 50 employees and generated €9 million of revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

Surgical equipment for different indications in ophthalmology and anterior segment conditions, innovative technology. Ultra-fast Femto Laser for #cataractsurgery, the only machine capable of performing a real #photoemulsification and removal of cataracted lens only with an Irrigation/aspiration cannula. Created in 2015 by @Fabrice Romano and 6 other co-founders, Keranova is the first company in the world able to bring to surgeons a new method for extracting the cataracted lens, by removing thousands of thin particles created with the ultra-fast laser. No more need for the phacoemulsification machine, just an irrigation/aspiration.

Limagrain is an agricultural biotechnology company that specializes in plant genetics, seed production, and crop improvement.

Lumibird Medical is the medical division of the Lumibird Group, an expert in fiber lasers, solid lasers, laser diodes, and medical equipment. Formed from the 2020 merger of three entities – Quantel Medical, Ellex and Optotek – specializing in diagnostic and treatment devices for ophthalmology and other medical fields, our company is recognized for its commitment to innovation and stands out as a world leader in ophthalmic equipment. Our mission is to improve the comfort of patients worldwide by optimizing the standard of care with innovative diagnostic and treatment solutions dedicated to the medical sector. More information in our website!

Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities.

Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).

At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health.

The first plant-microbiome systems bioengineered to purify indoor air.

NEUROFIT, founded in 1996, is a pre-clinical CRO (Contract Research Organization) based in France and offering a comprehensive list of disease models and screening assays in the fields of psychiatry, neurology, multiple sclerosis, diabetes and pain. Neurofit works for major pharmaceutical and Biotech companies in Europe and the USA. Neurofit's core expertise in CNS and PNS includes animal behavior techniques, nerve conduction velocity measure, nerve fiber morphometry, primary neuronal cell cultures. Neurofit has long-standing experiences in psychiatric, neurodegenerative and autoimmune / inflammatory disorders. Our disease models are clinically relevant and predictive. Neurofit routinely performs, as part of a study, collection of blood, serum plasma, cerebrospinal fluid as well as dissection of brain microstructures from compound-treated animals to provide customers with useful samples for their pharmacokinetic, biochemistry and immunochemistry analyses.

Say yes to what's next! NextPharma, your CDMO partner for pharmaceutical development and manufacturing with fast, flexible and personalised solutions for worldwide markets. We are a leading European contract manufacturer in the pharmaceutical, nutraceutical, biotech and healthcare industries. For us, the most important step is always the next. Welcome to NextPharma! Because speed drives us, fills our working world with dynamism and allows us to grow. Our best recipe for joint success: space for passion. Because we are sure: Where excellent service inspires, passion is the best medicine. Our 2,300 European employees are located in our centres of excellence in Berlin, Bielefeld, Goettingen and Waltrop (Germany), Limay and Ploermel (France), Tampere (Finland), Edinburgh (UK) and Asker (Norway). NextPharma develops and produces a broad range of pharmaceutical dosage forms: • Solids (tablets, hard and soft capsules, powders, controlled-release pellets) • Non-sterile liquids (emulsions, suspensions, syrups, solutions) • Sterile liquids (ophthalmic and otic solutions and emulsions) • Semi-solids (creams, gels, ointments, suppositories) Special containment areas are available for: • Hormones (solid and semi-solid) • Narcotics (controlled substances) • Penicillin and Cephalosporin beta lactam antibiotics (solids and dry syrups) • Highly-potent compounds (soft gel and liquid-filled hard capsules) • Clinical trials services Career opportunities: Passion meets prospects! Joining NextPharma means taking the next step. A strong step forward. Because you will be adding prospects to your passion. With vision. Whether you are a school-leaver, an entry-level candidate, a specialist or an executive: the pharmaceutical, nutraceutical, biotech and healthcare industries are full of challenges and future potential. And it’s a future that we at NextPharma want to shape. Together with you! #speed #passion #service

At Novacyt, we pride ourselves on concentrating our expertise on specific market needs. Offering a comprehensive and developing portfolio of quality products, backed by proven supply and delivery services, to ensure the highest possible standards of customer service around the world. Our passion is for customer-centric solutions that advance the science behind diagnostics. This fuels our drive to deliver products that save lives and help in the fight against infectious disease. We offer an increasing portfolio of in-vitro diagnostic tests, utilising molecular and protein detection technologies – supporting healthcare and disease prevention across the globe in the clinical and life science sectors. Deep strengths in product development, commercialisation, contract design, and manufacturing ensure quality products and robust supply. Our Group has specialist experience and expertise throughout our business units: Primerdesign, Microgen Bioproducts, IT-IS international, and Lab21 Healthcare – creating solutions for the diagnostics industry, supplying an extensive range of high-quality assays and reagents worldwide.

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

Novaptech develops aptamer-based tools in the frame of technology transfer and innovation projects. Novaptech’s expertise is focused on the identification and the characterization of aptamers for biotechnological development of analytical and diagnostic aptamer projects. Novaptech develops collaborative projects or service agreements with academic laboratories and R&D department of companies. Novaptech works in close association with Dr. Toulmé ’s team, an academic laboratory (Inserm U1212, Bordeaux) which has more than 26 years of experience in aptamer selection.

Novian Health is a late-stage development medical device company based in Chicago, with a subsidiary, Novian Health SAS, in France. Novian Health has developed Novilase, a minimally invasive alternative to lumpectomy for the treatment of breast tumors using Interstitial Laser Therapy (ILT). Novian Health has received a CE Mark for focal destruction of malignant and benign breast tumors, the first thermal ablation device to be approved for breast cancer. Novian Health’s technology enables breast surgeons and radiologists to ablate tumors with image-guided laser therapy. Novilase offers significant advantages over surgery including fewer retreatments, quicker recovery, less pain and fatigue, minimal scarring, and only requires local anesthesia. Novian will conduct a multicenter pivotal trial to evaluate Novilase® laser therapy as a treatment for early-stage breast cancer. U.S. market clearance for the focal destruction of malignant tumors will be sought. Novian will begin commercialization in Europe. Novian Health has received U.S. FDA 510(k) clearance for the treatment of fibroadenomas, or benign breast tumors, and ablation of soft tissue. A registry has been initiated to collect additional information on benign breast tumors treated at centers around the U.S. www.novianhealth.com www.novilase.com

AI in the service of precision medicine. We don't perform miracles, just create the tools that enable them. At Okeiro, we develop medical AI solutions that transform the monitoring of transplant patients and those with chronic conditions. Our predictive algorithms, scientifically validated digital biomarkers, convert complex medical data into information directly usable by healthcare teams. This technology allows us to: - Detect early signals of complications or graft rejection - Personalize each treatment for truly proactive care - Intervene before critical symptoms appear Our goal is clear: to tangibly improve patients' lives by equipping healthcare professionals with innovative tools that make a daily difference. In close collaboration with healthcare professionals and pharmaceutical companies, we accelerate the clinical validation of therapeutic innovations to make new treatments more quickly accessible to the patients who need them!

We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

OneOne's mission is to support farmers in reducing their dependency on problematic agrochemicals. Our platform technology allows for the discovery and delivery of optimized microbes capable of enhancing crop nutrition, health, and growth, along with soil vitality.

OPIA Technologies is a company dedicated to the development of medical devices with a specialization in ophthalmology but also provides services for medical devices compagnies. One of the main goals is to provide innovative and reliable devices to improve the diagnosis and care of patients with ocular diseases. OPIA is building a complete portfolio of medical devices for sampling ocular surface components (conjunctiva: EYEPRIM , tear film: TEARPRIM) and for non-invasive ocular drug delivery (IONTOFORVET), based on proprietary patents. Activities encompass the whole life cycles of the devices. The team of Opia design, manufacture and warrants the regulatory and quality conformity of its medical devices. Opia benefits from a privileged relationship with JB TECNICS (www.groupejbt.com), a worldwide group specialized in tool manufacturing and clean room molding for the medical industry. OPIA meets the highest level of quality requirements with a certified ISO 13485 quality management system (QMS). OPIA Technologies is also part of the company alliance JBT HUB UP (www.jbt-hubup.com) which offers a global solution for the development of complex medical devices, from inception to commercialization. The services provided by Opia Technologies for medical device companies concerns the following fields: - Project management - R&D - Proof of concept - Regulatory affairs - CE-marking and - Intellectual property/patents - Marketing strategy www.eyeprim.com www.iontoforvet.com

Recordati Rare Diseases Inc. (RRD) markets products to treat rare diseases. RRD is a member of the Recordati Group, which includes Recordati S.p.A., Orphan Europe, among other companies around the globe. The Recordati Group, which was established in 1926 currently employs more than 4,000 worldwide. The RRD mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.

OXELTIS is an independent medchem oriented service company managed by former researchers from Idenix Pharmaceuticals and located in Montpellier - France. Oxeltis is a company that delivers integrated solutions for managing and executing medicinal and fine organic chemistry projects. We run FTE programs (hit to lead optimization) with an expertise in some specialty chemistry such as macrocycles (pseudopeptides), mono & poly/oligosaccharides (sugar phosphates, iminosugars, saccharidic antigens…) nucleos(t)ides (modified nucleosides, phosphoramidites…), short peptides, linkers and PROTACs (Ligands E3 CRBN ligase library ) applied to discovery programs in oncology, antivirals and antibiotics mainly. OXELTIS client portfolio includes 40+ European and US companies from biotech to top 10 pharmaceutical companies. With its team of experienced medchem chemists, OXELTIS is proactive in providing rapid, high quality and competitive work. Specific expertise: - Contract research in medicinal chemistry, FTE programs for hit to lead optimization in different fields including antivirals, anticancer and antibiotics. - Fee-for-service custom synthesis expertise in heterocycles (in various fields), modified sugars (sugar phosphates, iminosugars, unnatural sugars…monosaccharides and oligosaccharides...), nucleoside/nucleotide (sugar and base-modified nucleosides, phosphoramidites…), macrocycles (e.g. antiviral antiproteases) . https://oxeltis.com/ https://twitter.com/Oxeltis_CRO

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection.The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.

Pili, carbon conscious color company Pili is the leader in bio-based colorants and pigments. Its unique fermentation and sustainable chemistry processes, enable the production of high-performance, and low-carbon colors. Its technology aims at decarbonizing the color industry by drastically reducing the use of chemicals and fossil resources, particularly oil. Its products are designed for the textile, inks, paints & coatings and plastics sectors. Founded in 2015, Pili operates from 3 different sites: Toulouse White Biotechnology (TWB), Paris and the Roches-Roussillon industrial platform in Isère. With around 40 employees to date, the company has invested over €35 million since its launch to industrialize its innovative processes.

Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services for viral and non-viral delivery. Custom plasmid vector design and plasmid and protein manufacturing was integrated into the offer in 2022 to expand the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards.

Prestwick Chemical is a French provider of smart libraries. For almost 20 years, the company, founded by Prof. Camille-Georges Wermuth, has provided medicinal chemistry services and screening libraries to accelerate small molecules drug discovery. Prestwick has a large portfolio of smart Libraries designed to ensure maximal chemical diversity, possibly to access new IP while remaining within reach of both low and high throughput screening processes. They are constantly updated and improved. Our clients have reported high quality hit generation rate. The Prestwick Chemical Library®, a unique collection of 1520 small molecules (95% of approved off-patent drugs) is our flagship and is mentioned in 400+ publications worldwide. New innovative collections continuously feed our portfolio: Our Prestwick Drug-Fragment library has been designed to optimize the chance of success in Hit finding using Fragment-based Drug Discovery. Prestwick Chemical became a brand of Greenpharma in 2021.

About Promise Proteomics Promise proteomics is an expert in the bioproduction of Stable Isotope Labelled monoclonal antibodies and proteins, considered as internal standards for absolute quantification by mass spectrometry. Promise Proteomics offers products and services in two main areas : • Stable isotope labelled and unlabelled protein and monoclonal antibodies. We offer a range of products and services for customized bioproduction. • Innovative kits dedicated to monoclonal antibody quantification by mass spectrometry. mAbXmise kits are ready-to-use sample preparation kits, including our stable-labelled mAbs as internal standards and all the required reagents and consumables. mAbXmise targets 20 t-mAbs on the market, used in various therapeutic areas.

ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner. Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined with our extensive scientific knowledge and experience ensures ProteoGenix to be a reliable partner for your antibodies, proteins, genes (cDNA) and peptides. Our custom services ensure a unique and tailored process to our clients revolving around four areas : Protein expression and purification in E. Coli, Yeast, Insect cells (baculovirus) and Mammalian Cells Monoclonal antibody production and Polyclonal antibody production Gene synthesis, sub-cloning and mutagenesis Peptide synthesis, purification and conjugation ProteoGenix also provides the research and academic communities with a wide range of commercial products available on our website such as antibodies, proteins, ELISA kits, tissue microarrays, chimera RNAi, molecular biology products as well as many more.

Founded in 1981 and based in Paris (France), Prothia has established itself in the world of medical devices and equipment and has acquired a particular understanding of cardiovascular, perinatal and rehabilitation applications. Our existing products and those in development create major global growth opportunities. We recently created our American structure in Massachusetts (Worcester). We look forward to meeting candidates interested in our field and our way of working. Prothia supports clinicians to help them achieve their therapeutic and diagnostic objectives. Listening attentively defines us. We strive to be helpful and do what we do well.

Quantum Surgical is a French company founded in Montpellier, France, speacialized in medical robotics and AI. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

Qynapse is a neuroimaging technology company founded in 2015, originating from the CATI consortium of neuroimaging research laboratories. Based in France, with offices in the U.S. and Canada, Qynapse is dedicated to enhancing the diagnosis and monitoring of central nervous system (CNS) disorders, including Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. The company focuses on improving accuracy and reliability in clinical and research environments through AI-driven solutions. Qynapse offers proprietary AI-powered tools for analyzing neuroimaging data, such as MRI and PET scans. Its key product, QyScore®, features an automated platform with 20 algorithms and over 200 measures for assessing neurodegeneration and neuroinflammation. The company also provides clinical trial solutions that significantly reduce image-reading variability, enhancing trial efficiency, and normative datasets that deliver precise imaging metrics for tracking disease progression. Qynapse serves pharmaceutical and biotech companies, healthcare providers, and researchers, aiming to improve patient outcomes and accelerate drug development timelines.

Build the first Radiological Foundation Model Bring the radiological image to GPT Share the world's top medical expertise through AI Bring the best specialist to every patient/researcher/company

Rime Bioinformatics is a research and development biotechnology company with a focus on bioinformatics. As studying the genome of phages is key to detect lysogeny, toxicity, or antibiotic resistance genes, bioinformatics plays acentral role in the R&D process that leads a phage to market. Rime Bioinformatics’ mission is to make high-performance bioinformatics accessible, thanks to their solutions based on expert bacteria and phage genome annotations.Their technologies yields a 5x better understanding of phages genomes than traditional methods. This allows higher throughput screening of candidate phages and provides solid evidence to support phage-based products' proofs ofconcepts. Rime Bioinformatics is focused on delivering state of the art analysis and high quality results, summarized in clear and comprehensive reports.

Established in 2015 and based in France, SafeHeal™ is a clinical stage medical device manufacturer. Specializing in the development of anastomosis protection devices for colorectal surgery, SafeHeal's premier device, Colovac, was invented by French surgeon Charam Khosrovani to eliminate the need for diverting ostomies in patients undergoing colectomy.

Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.

Scipio bioscience had to cease its operations on 18/09/2024. At Scipio bioscience we were passionate about empowering every researcher to discover the molecular mechanisms of life for better health and a sustainable world. Enabling deeper insights into disease understanding, Scipio wanted to boost the access to and increases the pace of discoveries with its Asteria benchtop kit for easy scRNA-seq sample preparation and its Cytonaut intuitive cloud-based data analysis software for biologists and bioinformaticians alike. Scipio provided all researchers with empowered autonomy to embrace the next step in single-cell, working with unaltered transcriptomic data for the highest-quality results and true biological information. Scipio bioscience was housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

Surgery-assisting machines

Making Spine Surgery Safer SpineGuard is a French innovative medical company dedicated to the deployment and adoption of DSG® (Dynamic Surgical Guidance), powerful radiation-free real time sensing technology platform that spans a broad spectrum of skeletal applications from bone drilling instruments to automated placement of bone implants. Uniquely positioned to change the game in orthopedic robotic surgery. Devices, built with the DSG technology, give real-time audio and visual feedback to the surgeons to secure and streamline skeletal implant placement for the benefit of patients, surgeons, operating room staff and healthcare providers. The PediGuard probes are the only devices with built-in DSG capability to improve the accuracy of pedicle screw placement. The PediGuard probes are handheld tools used by spine surgeons to perform pilot holes in the vertebrae before pedicle screw placement. An electrical conductivity measurement sensor, located at the tip of the drilling instruments, alerts the surgeon in real time and without using X-Ray imaging, about changes in conductivity that occur at the transition between cancellous bone, cortical bone and soft tissues/ blood. These devices are used in surgeries for all kind of patients, from pediatric in deformity corrections to adult in degenerative diseases requiring internal fixation. These medical devices have assisted spine surgeons in accurately placing pedicle screws in over 90,000 spinal procedures around the world. With mounting clinical evidence (24 major Peer-Reviewed publications) confirming its efficacy, PediGuard devices are becoming a compelling answer to the clinical needs associated with safe and accurate pedicle screw placement.

Created in 1945 as a pharmaceutical company, Diagnostica Stago is now a world leader in the In-Vitro Diagnostics industry. Global, privately-owned and independent, Stago is fully dedicated to the exploration of Thrombosis and Haemostasis. Day in and day out, Stago is committed to enhancing the quality of healthcare by offering laboratories advanced testing systems and superior services, the fruit of our expertise and know-how in Haemostasis (reagents, instruments and disposables). Distributed in over 110 countries through a network of subsidiaries and exclusive distributors, we are in a position to guarantee our customers superior service and a product portfolio meeting the demands of global healthcare systems. Today, 90% of our production, developed and made in France, is exported. Specialising in the field of coagulation for over 60 years, Stago has acquired solid industrial experience (R&D, standardisation and production) in the field of In Vitro Diagnostics and lasting recognition from the scientific community. The field of biomedical science is constantly evolving and expanding; new discoveries are moving medicine increasingly towards individual treatments that require diagnostic markers and ever more precise exploratory tools. These are our challenges of tomorrow. Stago, relying on strong human and technological potential, will still have much to contribute in the years to come.

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world's first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech

Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Tribun Health powers the digital transformation of cancer diagnosis by designing innovative solutions. These solutions enable the management, analysis and sharing of cellular images for both diagnostic laboratories and pharmaceutical/biotech companies. The company offers customized support in digital pathology, focused on the customer’s expectations. In the field of image analysis, our solutions are based on the latest innovations in terms of artificial intelligence, notably deep and machine learning algorithms. These tools support physicians and researchers in their diagnostic decision-making and scientific evaluation for the sake of patients. In the field of sharing, our solutions implement full web tools to support our customers in their telepathology, teaching or multi-centric clinical validation activities.

Université de Bordeaux is a higher education institution offering a wide range of academic programs and conducting research.

Urgo Medical is the wound-healing division of URGO group. Every day our 1600 employees are passionate about creating, developing and promoting highly innovative dressings and global solutions to heal people suffering from wounds. Our mission, as The Healing Company, is to make a significant difference for patients, healthcare professionals and the healthcare systems. In order to fulfil our mission: • Patient is at the heart of everything we do. • We keep innovating to develop the best in class solutions. • We have a pioneer and entrepreneurial mindset and we dare to take risks to find new solutions. This is why we are different. This is why we can make a difference. Our innovation and conqueror mindset enables us to be a dynamic Advanced Wound Care company.

UroMems was founded in 2011 and focuses on designing, developing and commercializing active implantable medical devices. The company is based at the heart of the French Silicon Valley, in the Sophia Antipolis technopark, near Nice, France.

Pioneer and expert in blood and tissue microbiota, Vaiomer carries out microbiota studies, in the fields of human and animal health, for preclinical and clinical research, CROs, dermocosmetics, nutraceuticals and pharmaceutical / biotech companies. We perform microbiota studies from a very wide variety of biological samples (blood, adipose tissue, biopsies, tumors, and more classically skin, saliva, faeces, etc.): DNA extraction, quantification by qPCR, sequencing metagenomics, Bioinformatics, Biostatistics. Upstream and downstream of the studies: support for the experimental design and the drafting of study protocols, then for the interpretation and valuation of the results. The role of tissue and blood microbiomes in systemic inflammation is studied in a wide variety of pathologies: https://vaiomer.com/microbiome-applications/ Microbiota can interact with compounds. The study of the action of a compound on the microbiota makes it possible to characterize the modulating, protective or toxic effects of the microbiota on the compound, or of the compound on the microbiota. Taking into account variations in the microbiota also makes it possible to derisk the translation from the animal model to humans: it is a new source of biomarkers of the therapeutic response (responders / non-responders). We are an expert multidisciplinary team (Scientific / Microbiota, Molecular Biology, Bioinformatics and Biostatistics), have a unique technology for samples of low bacterial biomass and a molecular biology laboratory that can process samples from infected subjects (COVID , HIV...)

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta's DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters. The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation. VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space. Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.

About us Since its creation in 1962, continuous technological and market research, implementation of latest technology at all levels, dedication to customer satisfaction and high quality and reliability standards are the key factors in Vygon's growth. Vygon's name has become synonymous with quality and reliability in the field of single-use medical and surgical products. Know-how Our industrial culture grew along with the company. We now have 11 factories worldwide, and we manufacture some 210 million medical devices every year. 9 of our factories are located in Europe, including 5 in France. We inspect the entire production line, from procurement of raw materials through to distribution logistics. We guarantee the traceability of our products and quality control. Every pack we deliver results from the know-how and commitment of multidisciplinary teams that work together and learn from each other - the driving force behind Vygon. Conceived and designed by our engineers and technicians and manufactured in one of our 11 plants, Vygon products meet ISO 13485 standards as well as the environmental ISO standard 14001. 60 years after its creation, our group now has the support of 26 subsidiaries and 11 production sites, including 8 in Europe. Thanks to the hard work of its 2,619 employees, Vygon manufactures nearly 210 million medical devices every year.

Xegen is a bioinformatics company specialized in Next Generation Sequencing (NGS) data analysis. We provide support for our customers or partners in their NGS data processing issues, through specific, automated, high added value bioinformatics analyzes. Xegen is developing Polypheme a bioinformatics suite dedicated to complex genes analysis (polymorphisms detection or allelic types). Polypheme analysis includes in particular HLA Typing, classic (HLA-A, -B, -C, DRB1, DQB1) and not classic genes (HLA-E, -F, -G, -H). Polypheme is also used to discover new alleles.